Frederick Altice, MD
Professor of Medicine, Yale University (Affiliate)
Frederick L. Altice, MD, after completing his clinical and research training at Yale University is the Director of Clinical and Community Research and he also directs the Community Health Care Van and the HIV in Prisons Program. He is trained in both infectious diseases and addiction medicine. Dr. Altice’s research interests are focused on the interface between infectious diseases and substance abuse. As a clinical epidemiologist, health services and intervention researcher, he has created novel programs for the treatment of HIV, HCV, and uberculosis in vulnerable populations, including injection drug users in HIV clinical, community and correctional settings. Specifically, he has been an international leader in research related to adherence to antiretroviral therapy, particularly among HIV+ drug users, has made considerable inroads into novel approaches using directly administered antiretroviral therapy and other structural interventions to facilitate adherence both nationally and internationally. Dr. Altice has been at the forefront of integrating buprenorphine and methadone treatment into managing co-morbid conditions, including the management of HIV, HCV, TB and mental illness.
He is the Principal Investigator on over 20 federally-funded grants, including numerous clinical investigations funded by the National Institutes on Health, the Substance Abuse and Mental Health Services Administration, Special Projects of National Significance for the Health Resources Services Agency and other federal agencies. Dr. Altice is currently directing studies that bridge the gap between the correctional and community setting, specifically on the use of directly observed antiretroviral therapy, opiate-substitution therapy and naltrexone treatment for alcohol dependence. In addition to publishing his research in peer-reviewed journals, Dr. Altice has authored several significant books and book chapters. He lectures nationally and internationally on the subject of HIV, viral hepatitis, substance abuse and the management of medically complicated patients. Current research includes methadone and buprenorphine as primary and secondary HIV prevention, directly administered antiretroviral therapy, depot-naltrexone as alcohol relapse prevention for HIV+ prisoners, peer-driven interventions, secondary prevention among drug users and prisoners and includes international projects in Malaysia, Ukraine and Iran.
List of Current Projects:
1. Randomized, placebo-controlled trial of depot-naltrexone for HIV+ prisoners with alcohol dependence who are transitioning to the community. Funding: NIAAA. Principal Investigators: Altice and Springer
2. Project Harapan: 2×2 Randomized controlled trial of methadone maintenance and Holistic Health Recovery Project among HIV+ prisoners with opioid dependence in Malaysia. Funding: NIDA. Principal Investigator: Altice
3. Project Connect: Randomized controlled trial of directly administered antiretroviral therapy among HIV+ prisoners with opioid dependence who are transitioning to the community. Funding: NIDA. Principal Investigator: Altice
4. Transitions: This is a Special Project of National Significance to develop and evaluate evidence-based models for integrating substance abuse treatment and contingency management into a comprehensive jail-release program. The program utilizes buprenorphine treatment as a conduit to care. Funding: HRSA Principal Investigator: Altice
5. Project Choices: This program builds on our previous SAMHSA work where we developed the first mobile buprenorphine induction and stabilization program in the country. In this project, we target our buprenorphine expansion for released prisoners with or at risk for HIV/AIDS. We also integrate other evidence-based interventions as part of the expansion and enhancement of services.
6. Project Bridge: Methadone and buprenorphine as primary and secondary HIV prevention, directly administered antiretroviral therapy, peer-drive interventions, and secondary prevention among drug users and prisoners, including international projects in Malaysia, Ukraine and Iran
American Board of Internal Medicine, Infectious Diseases, 1992
American Board of Internal Medicine, Internal Medicine, 1989
M.D., Emory University, 1986
M.A., Universidad de Santiago de Compostela, Spain, 1982 (Spanish literature)
B.A., Texas A&M University, 1982 (biology and Spanish)
|Mailing Address||Yale University135 College Street, Suite 323New Haven, CT 06510|